Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT05579769
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
- Conditions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-10-04
- Target Recruit Count
- 32
- Registration Number
- NCT05566535
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-10-06
- Target Recruit Count
- 400
- Registration Number
- NCT05491304
- Locations
- 🇨🇳
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 87
- Registration Number
- NCT05447260
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Peter Hosein, MD
- Target Recruit Count
- 35
- Registration Number
- NCT05440942
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05413356
- Locations
- 🇨🇳
The first Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 130
- Registration Number
- NCT05410470
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
- Conditions
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 70
- Registration Number
- NCT05398809
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT05371964
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Texas Oncology, Tyler, Texas, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
Topical Ruxolitinib in Chronic Hand Dermatitis
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 16
- Registration Number
- NCT05293717
- Locations
- 🇺🇸
UR Medicine Dermatology College Town, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.